|
BPHL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.677700E-03 |
| Normal-vs-Stage3 |
4.2854608750531E-14 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
6.944900E-03 |
| Stage1-vs-Stage3 |
3.586400E-01 |
| Stage1-vs-Stage4 |
1.315990E-02 |
| Stage2-vs-Stage3 |
2.969600E-02 |
| Stage2-vs-Stage4 |
2.596000E-04 |
| Stage3-vs-Stage4 |
5.100500E-03 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.67821312402339E-12 |
| Normal-vs-Asian |
1.65978342181461E-12 |
| Caucasian-vs-AfricanAmerican |
7.063200E-03 |
| Caucasian-vs-Asian |
5.591900E-02 |
| AfricanAmerican-vs-Asian |
5.081400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.65290003906193E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
8.693200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
3.88120002803305E-09 |
| Normal-vs-Age(81-100Yrs) |
2.419800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.400600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.130400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.479600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.075600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.040400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.806800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.085630E-01 |
| Classical-VS-Follicular |
1.406170E-01 |
| Classical-VS-Other |
7.576600E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
9.356200E-01 |
| Tall-VS-Other |
9.799800E-01 |
| Tall-VS-Normal |
2.76570000234955E-09 |
| Follicular-VS-Other |
9.516600E-01 |
| Follicular-VS-Normal |
3.86959997378256E-09 |
| Other-VS-Normal |
9.799700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.6503465261053E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.033800E-04 |
|
|
